Feasibility and Tolerability of Eribulin-Based Chemotherapy Versus Other Chemotherapy Regimens for Patients With Metastatic Triple-Negative Breast Cancer: A Single-Center Retrospective Study

    February 2024 in “ Frontiers in Cell and Developmental Biology ”
    Weiwei Huang, Chenxi Wang, Lili Wang, Yangkun Shen, Qi Chen, Zhijian Huang, Jian Liu, Xiaoyan Lin, Fan Wu, Xinhua Chen, Nani Li, Yi Hong, Mulan Chen, Jieyu Li, Chuanzhong Huang
    TLDR Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
    This retrospective study at Fujian Medical University Cancer Hospital assessed the feasibility and tolerability of eribulin-based chemotherapy in 159 patients with metastatic triple-negative breast cancer (TNBC). Eribulin-based treatment showed significantly longer median progression-free survival (PFS) and overall survival (OS) compared to platinum-based and nab-paclitaxel-based regimens, with hazard ratios indicating substantial survival benefits. Eribulin was also associated with fewer adverse effects, such as anemia, peripheral neuropathy, nausea, vomiting, and hair loss. These results suggest that eribulin is a promising treatment option for advanced TNBC, warranting further investigation in larger randomized trials.
    Discuss this study in the Community →